About Laigo Bio
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Seed
Global Headquarters
Utrecht, The Netherlands
Tracked Since
Oct 2, 2026
Web & Domain Identity
Official Website
laigobio.com
Domain Registered Date
Dec 1, 2021
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Company Profile
Company Milestones & Timeline
- Capital Raise
Raised $19,700,000 · Seed
news.google.com
- Milestone
Website domain registered
laigobio.com
Investors & Backers
Investor firms and individual backers were not publicly disclosed in available round filings for Laigo Bio.
Funding History
Seed equity
· Mar 23, 2026
$19,700,000 news.google.com
Founders & Leadership
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026